Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary ...

Pharmacokinetics, safety, and efficacy of bosentan in pediatric ...

The pharmacokinetics of bosentan in pediatric patients with pulmonary arterial hypertension and healthy adults are similar, and treatment with bosentan ...

Bosentan: in pediatric patients with pulmonary arterial hypertension

A noncomparative, multicenter, phase III trial (FUTURE-1), which was primarily designed to investigate the pharmacokinetics of dispersible bosentan in pediatric ...

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial ...

The terminal elimination half-life (t1/2) is about 5.4 h and is unchanged at steady state in healthy adult subjects with a 50% bioavailability.

Pharmacokinetics, safety, and efficacy of bosentan in pediatric ...

Conclusions: The pharmacokinetics of bosentan in pediatric patients with pulmonary arterial hypertension and healthy adults are similar, and treatment with ...

Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary ...

Bosentan PK parameters obtained with both methods were compared by the geometric mean ratio (GMR; DBS/plasma) and its 90% CI after correction ...

Pharmacokinetics of Bosentan in Routinely Treated Japanese ...

We evaluated the pharmacokinetics of routinely administered bosentan in 46 Japanese pediatric patients with pulmonary arterial hypertension.

Pharmacokinetics, safety, and efficacy of bosentan in pediatric ...

The pharmacokinetics of bosentan in pediatric patients with pulmonary arterial hypertension and healthy adults are similar, and treatment ...

11 Use of Bosentan in Pediatric Pulmonary Hypertension

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372-82. 5 ...

Pharmacokinetics of Bosentan in Routinely Treated Japanese ...

We previously reported that the pharmacokinetics of bosentan varied greatly in pediatric patients with pulmonary arterial hypertension; that is, a more than ...

Safety Experience With Bosentan in 146 Children 2–11 Years Old ...

In a retrospective study of 86 pediatric patients primarily with IPAH or PAH related to congenital heart disease, bosentan improved or maintained World Health ...

Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary ...

Bosentan concentrations measured by DBS were therefore good estimations of bosentan plasma concentrations, and DBS can be considered a valid alternative to ...

Efficacy, safety and pharmacokinetics of bosentan in ...

A number of such reports suggest that the dual endothelin receptor antagonist (ERA) bosentan is well tolerated and effective in this population [12–18]. In a ...

A bosentan pharmacokinetic study to investigate dosing regimens in ...

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE‐3

Pharmacokinetics of Bosentan in Routinely Treated Japanese ...

Summary: We evaluated the pharmacokinetics of routinely administered bosentan in 46 Japanese pediatric patients with pulmonary arterial hypertension.

Population Pharmacokinetics of Tadalafil in Pediatric Patients with ...

Other covariate effects were that bosentan increased CL/F, V/F decreased with decreasing body weight, and bioavailability (F) decreased with ...

Long-term efficacy of bosentan in treatment of pulmonary arterial ...

In adults with IPAH, the survival of patients treated with bosentan as a first-line therapy with the addition of other medicines as indicated was reported as 92 ...

Summary of bosentan pharmacokinetic parameters by dosing ...

24 Also, bosentan has been reported as safe to use in pediatric patients with PAH in the repeated FUTURE study by Berger et al. 25, 26 There was not the same ...

Treatment of pulmonary arterial hypertension in children - Gorenflo

Another small, placebo-controlled study of bosentan, which was dosed based on weight ranges, in pediatric Fontan patients (n=5 bosentan vs. n=4 placebo) aged ...

Bosentan: in pediatric patients with pulmonary arterial hypertension.

A noncomparative, multicenter, phase III trial (FUTURE-1), which was primarily designed to investigate the pharmacokinetics of dispersible bosentan in pediatric ...

Bosentan: Uses, Interactions, Mechanism of Action | DrugBank Online

ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this ...